Production (Stage)
REGENXBIO Inc.
RGNX
$10.35
$1.5016.95%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 319.59% | -12.33% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 319.59% | -12.33% | |||
| Cost of Revenue | 137.23% | -327.23% | |||
| Gross Profit | -81.22% | 506.01% | |||
| SG&A Expenses | 35.19% | -22.51% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -98.20% | 2,151.35% | |||
| Total Operating Expenses | 5.93% | -15.87% | |||
| Operating Income | 123.61% | 17.25% | |||
| Income Before Tax | 111.88% | 14.11% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 111.88% | 14.11% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 111.88% | 14.11% | |||
| EBIT | 123.61% | 17.25% | |||
| EBITDA | 133.97% | 18.54% | |||
| EPS Basic | 111.77% | 14.23% | |||
| Normalized Basic EPS | 111.77% | 14.23% | |||
| EPS Diluted | 111.77% | 14.23% | |||
| Normalized Diluted EPS | 111.75% | 14.23% | |||
| Average Basic Shares Outstanding | 0.97% | 0.14% | |||
| Average Diluted Shares Outstanding | 1.11% | 0.14% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||